Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9


Polymorphism of nanocrystalline TiO2 prepared in a stagnation flame: formation of the TiO2-II phase.

Manuputty MY, Dreyer JAH, Sheng Y, Bringley EJ, Botero ML, Akroyd J, Kraft M.

Chem Sci. 2018 Nov 14;10(5):1342-1350. doi: 10.1039/c8sc02969e. eCollection 2019 Feb 7.


Size spectra and source apportionment of fine particulates in tropical urban environment during southwest monsoon season.

Zong Y, Botero ML, Yu LE, Kraft M.

Environ Pollut. 2019 Jan;244:477-485. doi: 10.1016/j.envpol.2018.09.124. Epub 2018 Oct 8.


The characterization and validation of 17β-estradiol binding aptamers.

Svobodová M, Skouridou V, Botero ML, Jauset-Rubio M, Schubert T, Bashammakh AS, El-Shahawi MS, Alyoubi AO, O'Sullivan CK.

J Steroid Biochem Mol Biol. 2017 Mar;167:14-22. doi: 10.1016/j.jsbmb.2016.09.018. Epub 2016 Sep 23.


Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trial.

Benlloch S, Botero ML, Beltran-Alamillo J, Mayo C, Gimenez-Capitán A, de Aguirre I, Queralt C, Ramirez JL, Ramón y Cajal S, Klughammer B, Schlegel M, Bordogna W, Chen D, Zhang G, Kovach B, Shieh F, Palma JF, Wu L, Lawrence HJ, Taron M.

PLoS One. 2014 Feb 25;9(2):e89518. doi: 10.1371/journal.pone.0089518. eCollection 2014.


Commentary: overcoming antibiotic resistance with Helicobacter pylori therapy--optimisation is the way forward; authors' reply.

Sierra F, Forero JD, Rey M, Botero ML, Cárdenas A.

Aliment Pharmacol Ther. 2013 Jul;38(2):205-6. doi: 10.1111/apt.12367. No abstract available.


Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication.

Sierra F, Forero JD, Rey M, Botero ML, Cárdenas A.

Aliment Pharmacol Ther. 2013 Jun;37(12):1165-71. doi: 10.1111/apt.12329. Epub 2013 May 8.


Automated microsystem for electrochemical detection of cancer markers.

Kellner C, Botero ML, Latta D, Drese K, Fragoso A, O'Sullivan CK.

Electrophoresis. 2011 Apr;32(8):926-30. doi: 10.1002/elps.201000667. Epub 2011 Mar 10.


NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J.

Cancer Res. 2008 Oct 1;68(19):8022-30. doi: 10.1158/0008-5472.CAN-08-1385.


Supplemental Content

Loading ...
Support Center